Robert Brenner Biography and Net Worth

Insider of Vera Therapeutics

Dr. Brenner brings more than 25 years of experience as a respected nephrologist and a successful biotechnology executive. Dr. Brenner has previously served in executive roles in several clinical-stage biotech companies, including Chief Medical Officer at Orionis Biosciences and SVP of Medical Affairs at AMAG Pharmaceuticals, contributing to the company’s first therapeutic approval and launch for iron deficiency anemia (Feraheme).

Previously, Dr. Brenner held several positions of expanding responsibility in the nephrology franchise at Amgen. During this time, he led kidney related global development programs, and supported two product approvals (Aranesp and Sensipar) and oversaw the establishment of the nephrology medical affairs organization. Dr. Brenner received his BA from Johns Hopkins University and his MD from Albert Einstein College of Medicine. He completed his medical residency at Brigham and Women’s Hospital and his nephrology fellowship at Stanford University Medical Center.

What is Robert Brenner's net worth?: The estimated net worth of Robert Brenner is at least $2.10 million as of February 23rd, 2026. Brenner owns 50,947 shares of Vera Therapeutics stock worth more than $2,098,252 as of February 27th. This net worth approximation does not reflect any other assets that Brenner may own. Learn More about Robert Brenner's net worth.
How old is Robert Brenner?: Brenner is currently 56 years old. There are 5 older executives and no younger executives at Vera Therapeutics. Learn More on Robert Brenner's age.
How do I contact Robert Brenner?: The corporate mailing address for Brenner and other Vera Therapeutics executives is , , . Vera Therapeutics can also be reached via phone at 650-770-0077 and via email at [email protected]. Learn More on Robert Brenner's contact information.
Has Robert Brenner been buying or selling shares of Vera Therapeutics?: Within the last three months, Robert Brenner has sold $90,298.98 in shares of Vera Therapeutics stock. Most recently, Robert Brenner sold 2,151 shares of the business's stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $41.98, for a transaction totalling $90,298.98. Following the completion of the sale, the insider now directly owns 50,947 shares of the company's stock, valued at $2,138,755.06. Learn More on Robert Brenner's trading history.
Who are Vera Therapeutics' active insiders?: Vera Therapeutics' insider roster includes Robert Brenner (Insider), Patrick Enright (Director), Marshall Fordyce (Founder), Marshall Fordyce (CEO and Founder), Sean Grant (CFO), David Johnson (COO), Maha Katabi (Director), Beth Seidenberg (Director), Laurence Skelton (Insider), and Joseph Young (CAO). Learn More on Vera Therapeutics' active insiders.
Are insiders buying or selling shares of Vera Therapeutics?: In the last year, Vera Therapeutics insiders bought shares 3 times. They purchased a total of 255,882 shares worth more than $5,527,583.36. In the last year, insiders at the sold shares 8 times. They sold a total of 48,490 shares worth more than $1,841,810.20. The most recent insider tranaction occured on February, 23rd when insider Robert Brenner sold 2,151 shares worth more than $90,298.98. Insiders at Vera Therapeutics own 16.3% of the company. Learn More about insider trades at Vera Therapeutics.
Information on this page was last updated on 2/23/2026.

Robert Brenner Insider Trading History at Vera Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/23/2026	Sell	2,151	$41.98	$90,298.98	50,947

Robert Brenner Buying and Selling Activity at Vera Therapeutics

Vera Therapeutics Company Overview

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Today's Range

Now: $40.73

$40.26

$41.71

50 Day Range

MA: $46.53

$40.95

$55.26

2 Week Range

Now: $40.73

$18.53

$56.05

Volume

805,193 shs

Average Volume

1,038,916 shs

Market Capitalization

$2.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.16

Robert Brenner Biography and Net Worth

What is Robert Brenner's net worth?

How old is Robert Brenner?

How do I contact Robert Brenner?

Has Robert Brenner been buying or selling shares of Vera Therapeutics?

Who are Vera Therapeutics' active insiders?

Are insiders buying or selling shares of Vera Therapeutics?